Skip to Main content Skip to Navigation
Journal articles

Lipid-lowering treatments and cardiovascular prevention in diabetic subjects: news and perspectives

Abstract : The atherosclerotic cardiovascular disease is the leading cau of death in diabetes. The treatment of the dyslipidemias and especially the exce of LDL-cholesterol (LDL-C) which is a major cardiovascul, risk factor allows the primary and the secondary preventic of cardiovascular events in diabetes. A new French consensus and guidelines from the Frenc National Authority for Health (HAS) have set the framewo for the management of dyslipidemias. Statins represent the first-line treatment of the excess of LDL The statin-fenofibrate association can be used in high ar very high cardiovascular risk patients with LDL-C at targ but with a residual atherogenic dyslipidemia. PCSK9 (Proprotein Convertase Subtilisin Kexin type 9) inhibitc are a new therapeutic class highly effective in the reduction LDL-C whose launch on the market is still pending in Franc
Document type :
Journal articles
Complete list of metadatas

https://hal-amu.archives-ouvertes.fr/hal-02091398
Contributor : Annick Prémilleux <>
Submitted on : Friday, April 5, 2019 - 4:27:36 PM
Last modification on : Wednesday, August 19, 2020 - 11:17:52 AM

Identifiers

  • HAL Id : hal-02091398, version 1

Collections

Citation

Rene Valero, Sophie Beliard. Lipid-lowering treatments and cardiovascular prevention in diabetic subjects: news and perspectives. CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2018, 22 (3-4), pp.84-89. ⟨hal-02091398⟩

Share

Metrics

Record views

22